Blue Horizon International, LLC — FDA Warning Letter, 2026-05-26: Unapproved New Drugs/Unlicensed Biological Product Violations
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Unlicensed Biological Product Violations
TL;DR
FDA issued a Warning Letter to Blue Horizon International, LLC on 2026-05-26 citing: Unapproved New Drugs/Unlicensed Biological Product Violations. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/blue-horizon-international-llc-728085-05262026
Argus analysis
Blue Horizon International, LLC (MARCS-CMS 728085) received an FDA Warning Letter dated May 26, 2026 from the Center for Biologics Evaluation and Research (CBER). The letter cites: Unapproved New Drugs/Unlicensed Biological Product Violations. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 2, 2026.
Unapproved-drug letters cite 21 USC 355 (new drug application requirement) or 21 USC 331(d) (introducing an unapproved new drug into interstate commerce). FDA has increasingly applied these provisions to online sellers of homeopathic products, topical anesthetics, and supplement-adjacent SKUs making unapproved drug claims.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same unapproved new drug category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Blue Horizon International, LLC MARCS-CMS 728085 — May 26, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via UPS and EMAIL Reference #: CBER 26-728085 Product: Biologics Recipient: Recipient Name Dr. Brian Mehling Recipient Title Chief Medical Officer and Founder Blue Horizon International, LLC 214 State Street Suite 101 Hackensack , NJ 07601 United States bmehling@bluehorizoninternational.com Issuing Office: Center for Biologics Evaluation and Research (CBER) United States WARNING LETTER May 26, 2026 CBER 26-728085 Dear Dr. Mehling: The United States Food and Drug Administration (FDA) reviewed your company’s website at https://bluehorizonstemcells.com (last visited May 2026), through which your company markets “Stem Cell Therapy” derived from umbilical cord blood and “Exosome Therapy” 1 derived from Wharton’s Jelly Mesenchymal Stem Cells (“WJ-MSC[s]”) for allogeneic use (hereafter, “your products”). This letter is to advise you that your misbranding of your products while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k). Unapproved New Drug and Unlicensed Biological Product Violations Based on information and records reviewed by FDA, including your website, https://bluehorizonstemcells.com, (last visited May 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and/or are intended to affect the structure or function of the body. For example, After identifying your products, and under the heading “What Can We Treat,” your homepage lists various diseases and conditions, including: o Digestive System Diseases, including Hepatic steatosis and Chronic pancreatitis o Respiratory Diseases, including Allergic rhinitis, Rhinitis, and Sinusitis o Rheumatic Diseases, including Lupus o Endocrine Diseases, including Hashimoto’s thyroiditis and Hypothyroidism o Musculoskeletal Diseases, including Myositis, and Sports-related injury complications o Cardiovascular Diseases, including Coronary artery disease Your home page states, “Our stem cell treatments use ethically sourced cells from umbilical cord blood and adipose tissue to treat chronic conditions, injuries, and degenerative diseases.” This statement is followed by a link to your stem cell treatment webpage and a list of uses for stem cells: “Tissue regeneration[;] Immune modulation[;] Anti-inflammatory effects[; and] Pain reduction”. Under the heading “Revolutionary Stem Cell Therapy,” your stem cell treatment webpage states, “Explore the power of stem cells in treating various medical conditions[,]” followed by, among other conditions and diseases: o Neurological Marvels …Spinal Cord Regeneration Stroke Recovery Multiple Sclerosis Relief o Cardiovascular Miracles …Myocardial Rejuvenation …Cardiomyopathy Triumph Reversing Atherosclerosis o Muscul…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Blue Horizon International, LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Blue Horizon International, LLC as of 2026-06-02. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Blue Horizon International, LLC — FDA Warning Letter, 2026-05-26: Unapproved New Drugs/Unlicensed Biological Product Violations. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-blue-horizon-international-llc-2026-05-26-unapproved-drug
"Blue Horizon International, LLC — FDA Warning Letter, 2026-05-26: Unapproved New Drugs/Unlicensed Biological Product Violations." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-blue-horizon-international-llc-2026-05-26-unapproved-drug.
Argus HQ Research. "Blue Horizon International, LLC — FDA Warning Letter, 2026-05-26: Unapproved New Drugs/Unlicensed Biological Product Violations." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-blue-horizon-international-llc-2026-05-26-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_blue_horizon_international_llc_2026_05_26_unapproved_drug_2026,
title = {Blue Horizon International, LLC — FDA Warning Letter, 2026-05-26: Unapproved New Drugs/Unlicensed Biological Product Violations},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-blue-horizon-international-llc-2026-05-26-unapproved-drug},
note = {Accessed: July 13, 2026}
}